A predictive model based on clinical and computed tomography enterography features to evaluate maintenance efficacy of anti-tumor necrosis factor-α monoclonal antibody in Crohn′s disease patients with small intestinal involvement
10.3760/cma.j.cn101480-20220428-00063
- VernacularTitle:基于临床-影像学特征构建模型预测抗肿瘤坏死因子-α单克隆抗体维持治疗小肠克罗恩病的疗效
- Author:
Pengyu YANG
1
;
Chuanding LI
;
Zhuoma DEJI
;
Zhanju LIU
;
Meiying ZENG
;
Xiaolei WANG
Author Information
1. 同济大学附属第十人民医院消化内科，上海 200072
- Publication Type:Journal Article
- Keywords:
Crohn′s disease;
Small intestinal involvement;
Computed tomography enterography;
Anti-tumor necrosis factor-α;
Monoclonal antibody;
Maintenance therapy
- From:
Chinese Journal of Inflammatory Bowel Diseases
2022;06(4):304-311
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To establish a model to predict the maintenance efficacy of anti-tumor necrosis factor (TNF) -α monoclonal antibody in active Crohn′s disease (CD) patients with small intestinal involvement.Methods:A retrospective cohort study was carried out. Ninety-eight CD patients with small intestinal involvement admitted in the Tenth People′s Hospital of Tongji University from January 2017 to December 2020 were consecutively included. All the patients received anti-TNF-α monoclonal antibody induction therapy regularly and the induced remission treatment was effective. The maintenance therapy was followed up for at least 1 year. All patients underwent computed tomography enterography (CTE) before treatment. According to whether therapeutic optimization occurred, the patients were divided into optimization group and maintenance group. Univariate analysis was used to compare the differences of clinical and CTE features between the two groups, and multivariate Logistic regression analysis was performed to select the independent factors for medication optimization. A nomogram based on the established predictive model was drawn and further validated internally.Results:During the follow-up, 40 patients underwent treatment optimization and 58 maintained the original treatment. Univariate analysis showed that compared with the maintenance group, the ages of onset[ (35.7±14.3) years old vs. (29.6±12.3) years old, P = 0.027) ] and diagnosis[ (37.7±17.8) years old vs. (30.6±11.1) years old, P = 0.006) ] were older, the level of hemoglobin [ (112.9±23.2) g/L vs. (126.9±26.5) g/L, P = 0.008] and serum albumin [ (38.1±5.0) g/L vs. (42.5±4.9) g/L, P<0.001] was lower in the optimization group, meanwhile the degree of intestinal wall enhancement (mild: 40.0% vs. 74.1%, moderate and severe: 60.0% vs. 25.9%, P = 0.001) and intestinal stenosis (no or suspicious: 47.5% vs. 87.9%, mild: 17.5% vs. 5.2%, moderate and severe: 35.0% vs. 6.9%, P<0.001) were significantly different between two groups. Multivariate analysis revealed that age at diagnosis ( OR = 1.051, 95% CI: 1.009-1.096, P = 0.018) , degree of intestinal wall enhancement ( OR = 3.807, 95% CI: 1.268-11.428, P = 0.017) and moderate-severe intestinal stenosis ( OR = 6.550, 95% CI: 1.640-26.165, P = 0.008) were the independent risk factors for treatment optimization, and high serum albumin level ( OR = 0.841, 95% CI: 0.747-0.946, P = 0.004) was the protective factor. The area under ROC of the established predictive model was 0.856 (95% CI: 0.779-0.933, P<0.001) with sensitivity of 82.5%, specificity of 81.0%, and accuracy of 95.9%. Conclusion:A model is established based on the CTE features including the degree of intestinal wall enhancement and intestinal stenosis combined with age at diagnosis and serum albumin level, it can predict the efficacy of anti-TNF-α monoclonal antibody in maintenance therapy among CD patients with small intestinal involvement.
